Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04372355 | Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients | PHASE2 | COMPLETED | 40 | — | — | Jun 19, 2019 | Jun 19, 2020 | Oct 22, 2020 | 1 | Thailand |
The mean change of HbA1c values between Baseline (Week 0) and Week 8 after the initial WF10 treatment
| Arm | Type | Description |
|---|---|---|
| Chlorite-based drug WF10 | EXPERIMENTAL | WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five |
| Name | Type | Description |
|---|---|---|
| WF10 | DRUG | WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks. |
Inclusion Criteria: * Patients diagnosed with Diabetes Mellitus type II * Patient male or female 18-80 years old * Presence of Diabetic foot ulcer/non-healed stump, starting at least 3 weeks before or infected wound degree 3-4 * HbA1c \> 8.5% * Hematocrit \> 30% Exclusion Criteria: * Kanofsky per...